Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

49.660
-0.540-1.08%
Volume:4.02M
Turnover:197.73M
Market Cap:329.59B
PE:35.97
High:50.200
Open:50.200
Low:48.020
Close:50.200
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.80
T/O Rate:1.56%
Dividend:0.23
Dividend Rate:0.47%
EPS(LYR):1.381
ROE:12.46%
ROA:7.02%
PB:4.37
PE(LYR):35.97
PS:8.99

Loading ...

Hong Kong Stock Market Update | Hengrui Pharma Surges Nearly 4% on First A-Share Buyback as Analysts Eye Growth in Non-Oncology Portfolio

Stock News
·
Sep 18

Movement Alert|HENGRUI PHARMA Rises 3.78% in Regular Trading, First A-Share Buyback Executed as BlackRock Raises Stake to 7.68%

Market Focus
·
Sep 18

Blackrock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.68% on Sept 14, HKEX Filing Shows

Reuters
·
Sep 17

Hengrui Pharma Repurchases 335,000 A-Shares for ESOP at RMB 43.29 Each, Equal to 0.005% of Issued Capital

Bulletin Express
·
Sep 17

Jiangsu Hengrui Pharmaceuticals Completes Initial Share Repurchase, Investing 14.5 Million Yuan

Stock News
·
Sep 17

HENGRUI PHARMA: BlackRock, Inc. Acquires Shares, Long Position Rises to 7.68%

HK Disclosure
·
Sep 17

Hong Kong Stock Market Update: Hengrui Pharma Surges Nearly 4% in Late Trading Following Dual Clinical Trial Approvals

Stock News
·
Sep 16

China's Jiangsu Hengrui Climbs on Clinical Trial Approval for Stroke Drug

Reuters
·
Sep 16

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Recaticimab Injection

MT Newswires Live
·
Sep 16

Movement Alert|HENGRUI PHARMA Rises 3.01% in Regular Trading, Dense Pipeline Milestones Boost Market Sentiment

Market Focus
·
Sep 16

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.17% on Sept 10 from 6.56% - HKEX

THOMSON REUTERS
·
Sep 15

Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials

Stock News
·
Sep 15

Chinese Drug Regulator Accepts Hengrui Pharmaceuticals Unit's Marketing Application for SHR-2004 Injection

MT Newswires Live
·
Sep 15

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Movement Alert|HENGRUI PHARMA Rises 3.2% in Regular Trading, Core ADC Pipeline Drug Included in Breakthrough Therapy Designation List

Market Focus
·
Sep 14

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

MT Newswires Live
·
Sep 14

Hengrui Pharma Gets China Nod for Two Indications of Hetrombopag Olamine Tablets

MT Newswires Live
·
Sep 10

Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets

THOMSON REUTERS
·
Sep 10

Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets

Stock News
·
Sep 10

Movement Alert|HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress

Market Focus
·
Sep 10